4502.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:45):

Stats
आज की मात्रा	3.19M
औसत मात्रा	4.48M
बाजार मूल्य	6 415.37B
EPS	¥0 ( 2024-02-01 )
अगली कमाई की तारीख	( ¥1.100 ) 2024-05-08
Last Dividend	¥90.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	36.36
ATR14	¥1.540 (0.04%)

मात्रा सहसंबंध

लंबा: 0.14 (neutral)

छोटा: 0.63 (weak)

Signal:(52.758) Neutral

Takeda Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Takeda Pharmaceutical सहसंबंध - मुद्रा/वस्त्र

0.19
( neutral )

0.17
( neutral )

-0.08
( neutral )

0.16
( neutral )

-0.28
( neutral )

0.18
( neutral )

Takeda Pharmaceutical वित्तीय

Annual	2022
राजस्व:	¥4 027.48B
सकल लाभ:	¥2 783.41B (69.11 %)
EPS:	¥204.29

FY	2022
राजस्व:	¥4 027.48B
सकल लाभ:	¥2 783.41B (69.11 %)
EPS:	¥204.29

FY	2022
राजस्व:	¥3 569.01B
सकल लाभ:	¥2 462.16B (68.99 %)
EPS:	¥147.14

FY	2021
राजस्व:	¥3 197.81B
सकल लाभ:	¥2 203.50B (68.91 %)
EPS:	¥240.72

Financial Reports:

No articles found.

Takeda Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥90.00 (N/A)	¥0 (N/A)	¥90.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Takeda Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.76 - low (58.20%) | Divividend Growth Potential Score: 4.33 - Stable (13.47%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥16.50	2000-03-28
Last Dividend	¥90.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥3 458.50	--
Avg. Dividend % Per Year	0.00%	--
Score	2.84	--
Div. Sustainability Score	4.76
Div.Growth Potential Score	4.33
Div. Directional Score	4.54	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

2.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8255.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7616.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6817.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
6171.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4912.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4072.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3288.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2335.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9278.T	Ex Dividend Junior	2024-05-30	Annually	0.00%
8020.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0427	1.500	9.15	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0125	1.200	9.58	10.00	[0 - 0.3]
returnOnEquityTTM	0.0263	1.500	-0.819	-1.228	[0.1 - 1]
payoutRatioTTM	1.619	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.064	0.800	9.68	7.74	[1 - 3]
quickRatioTTM	0.465	0.800	-1.972	-1.578	[0.8 - 2.5]
cashRatioTTM	0.126	1.500	-0.409	-0.614	[0.2 - 2]
debtRatioTTM	0.328	-1.500	4.53	-6.80	[0 - 0.6]
interestCoverageTTM	1.450	1.000	-0.574	-0.574	[3 - 30]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.692	-1.500	7.23	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.675	1.000	2.08	2.08	[0.2 - 0.8]
operatingProfitMarginTTM	0.0750	1.000	-0.500	-0.500	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.157	1.000	-0.240	-0.240	[0.2 - 2]
assetTurnoverTTM	0.293	0.800	-1.379	-1.103	[0.5 - 2]
Total Score				4.76

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.00	1.000	6.47	0	[1 - 100]
returnOnEquityTTM	0.0263	2.50	-0.526	-1.228	[0.1 - 1.5]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	4.60	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.619	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.927	1.500	7.15	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.175	1.000	8.11	0	[0.1 - 0.5]
Total Score				4.33

Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.